A closer look at GLP-1 drug development There are several approved therapies to date that form the GLP-1 receptor agonist (GLP-1 RA) peptide class
With a focus on tailored care, were here to help you feel your best
Why CKD Changes the Retatrutide Conversation Kidney disease amplifies small problems
Olfaction under metabolic influences
As a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors, Phase 2 data demonstrated substantial effects on weight reduction and metabolic parameters, placing the molecule at the center of scientific and industry discussions
Conversely, the M2 phenotype is generally considered anti-inflammatory and has been associated with enhanced phagocytic activity, potentially reducing the risk of AD and its progression [99]